Hu Li-hong, Wu Yue, Lu Guo-hua, Chen Qing-yong, Wang Yue-hong, Zhou Jian-ying
Department Respirology Medicine, The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou 311200, China.
Zhonghua Zhong Liu Za Zhi. 2010 Oct;32(10):762-6.
To explore the expression of III β-tubulin and MDR1 protein in patients with non-small cell lung cancer (NSCLC), and to clarify its clinical significance.
Paraffin embedded tissues from 158 primary non-small cell lung cancers and para-cancerous lung tissues were investigated for the expression of III β-tubulin and MDR1 protein by immunohistochemistry, as well as in freshly-taken NSCLC tissues by Western blot. The relationship between the expression of III β-tubulin and MDR1 and the biological features of lung cancer was analyzed.
The positive rate of III β-tubulin and MDR1 protein expression in lung cancer tissues was 65.19% and 51.27%, respectively. Western blot analysis showed that the level of of III β-tubulin and MDR1 protein in NSCLC tissues was remarkably higher than that in normal tissues (P < 0.01). The expression of III β-tubulin in stage III-IV cases was significantly higher than that in stage I-II cases (P < 0.05), while the expression of MDR1 protein showed no significant difference (P > 0.05). The positive rate of III β-tubulin expression in well-moderate pathological grades was lower than that in poor ones. The positive rate of MDR1 expression in adenocarcinoma was higher than that in squamous cell carcinoma and large cell undifferentiated cancers (P < 0.01). The positive rate of expression of MDR1 protein and III β-tubulin was not correlated with sex, age, tumor size and lymph node metastasis (P > 0.05).
The expression of III β-tubulin and MDR1 may play an important role in the development and progression of human non-small cell lung cancer, and could be looked as an important index for judging the prognosis of lung cancer.
探讨Ⅲβ-微管蛋白和多药耐药蛋白1（MDR1）在非小细胞肺癌（NSCLC）患者中的表达情况，并阐明其临床意义。
采用免疫组织化学法检测158例原发性非小细胞肺癌及癌旁肺组织石蜡包埋标本中Ⅲβ-微管蛋白和MDR1蛋白的表达，同时采用蛋白质印迹法检测新鲜获取的NSCLC组织中二者的表达。分析Ⅲβ-微管蛋白和MDR1表达与肺癌生物学特性之间的关系。
肺癌组织中Ⅲβ-微管蛋白和MDR1蛋白的阳性表达率分别为65.19%和51.27%。蛋白质印迹分析显示，NSCLC组织中Ⅲβ-微管蛋白和MDR1蛋白水平显著高于正常组织（P<0.01）。Ⅲβ-微管蛋白在Ⅲ-Ⅳ期病例中的表达显著高于Ⅰ-Ⅱ期病例（P<0.05），而MDR1蛋白表达差异无统计学意义（P>0.05）。在病理分级为高-中分化的病例中，Ⅲβ-微管蛋白的阳性表达率低于低分化病例。腺癌中MDR1的阳性表达率高于鳞癌和大细胞未分化癌（P<0.01）。MDR1蛋白和Ⅲβ-微管蛋白的阳性表达率与性别、年龄、肿瘤大小及淋巴结转移无关（P>0.05）。
Ⅲβ-微管蛋白和MDR1的表达可能在人类非小细胞肺癌的发生发展中起重要作用，可作为判断肺癌预后的重要指标。
